REMARKS/ARGUMENTS

Claims 12-16 have been amended. Support for the amendment is found at specification page 7, paragraph [0011] and in original Claim 12. No new matter has been added.

Applicants thank the Examiner for the indication of allowable subject matter in Claims 1-11 and 16-22.

The rejection of Claims 12-15 under 35 U.S.C. 102(b) as being anticipated by Kazuya et al (JP 05027430) is traversed. The Office has indicated that Compound (9) of <u>Kazuya</u> anticipates formula (2). In response, formula (2) has been deleted from Claim 12. Furthermore, <u>Kazuya</u> does not suggest or disclose any compounds of remaining formulas (3) to (8). The rejection should be withdrawn.

Consequently, in view of the present amendment, no further issues are believed to be outstanding in the present application, and the present application is believed to be in condition for formal allowance. An early and favorable action is therefore respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, L.L.P. Norman F. Oblon

Customer Number 22850

Tel: (703) 413-3000 Fax: (703) 413 -2220 (OSMMN 08/09) Soonwuk Cheong

Registration No. 62,793